Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against ...

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...

A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors. The biotech ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) gapped down prior to trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $28.00 to $24.00.

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $38.00. Discover outperforming stocks and ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Jan 6 (Reuters) - Denali Therapeutics (DNLI.O), opens new tab said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic ...

Also Read: Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic Key secondary endpoints, measuring muscle strength and respiratory function, were also not statistically ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...